Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08, Zacks reports. The company had revenue of $3.17 million for the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%.
Voyager Therapeutics Stock Up 4.5%
VYGR stock traded up $0.14 during trading on Friday, hitting $3.27. The company had a trading volume of 469,234 shares, compared to its average volume of 651,966. The firm has a 50-day moving average price of $3.42 and a 200-day moving average price of $3.74. The firm has a market cap of $197.57 million, a PE ratio of -1.66 and a beta of 1.31. Voyager Therapeutics has a 1-year low of $2.93 and a 1-year high of $5.55.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on VYGR. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. Finally, Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $16.50.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of VYGR. Opaleye Management Inc. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $4,704,000. AQR Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after acquiring an additional 206,758 shares during the period. Two Sigma Investments LP acquired a new position in Voyager Therapeutics during the third quarter worth $657,000. Finally, Sphera Funds Management LTD. boosted its position in Voyager Therapeutics by 70.1% during the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock worth $1,335,000 after purchasing an additional 140,000 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.
Featured Stories
- Five stocks we like better than Voyager Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
